PDCD1 and non-small cell lung carcinoma: Recent studies in non-small cell lung cancer (NSCLC) have shown that patients who developed acquired resistance to PD-1/PD-L1 inhibitors experienced a loss of several mutation-associated neoantigens during treatment.